Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases

Pierre Payoux; Jean-Philippe Ranjeva

doi:10.1016/j.therap.2020.12.008

Contributions of PET and MRI imaging in the evaluation of CNS drugs in human neurodegenerative diseases

Therapie. 2021 Mar-Apr;76(2):121-126. doi: 10.1016/j.therap.2020.12.008. Epub 2020 Dec 5.

Authors

Pierre Payoux¹, Jean-Philippe Ranjeva²

Affiliations

¹ Inserm, UPS, ToNIC, Nuclear Medicine Department, Toulouse NeuroImaging Center, University Hospital of Toulouse France, Université de Toulouse, 31000 Toulouse, France. Electronic address: payoux.p@chu-toulouse.fr.
² CNRS, CRMBM, Aix-Marseille University, 13385 Marseille, France; CEMEREM, AP-HM, University Hospital Timone, 13385 Marseille, France.

PMID: 33563477
DOI: 10.1016/j.therap.2020.12.008

Abstract

This manuscript reviews the contributions of the neuroimaging methods including PET, conventional and advanced MRI methods to monitor the effect of new disease modifying drugs in neurodegenerative diseases. It now seems obvious that in many pathologies these two techniques are more and more complementary.

Keywords: Clinical trials; MRI; Neurodegenerative diseases; Neuroimaging; PET.

MeSH terms

Humans
Magnetic Resonance Imaging
Neurodegenerative Diseases* / diagnostic imaging
Neuroimaging
Pharmaceutical Preparations*
Positron-Emission Tomography

Substances

Pharmaceutical Preparations